Molecular Data Is Now Picking Pancreatic Cancer's First Drug

When a pancreatic cancer diagnosis lands, the first decision an oncologist faces is which of two chemotherapy regimens to prescribe. One, FOLFIRINOX, is an aggressive four-drug combination with severe side effects including nerve damage. The other, gemcitabine/nab-paclitaxel, is generally more tolerable. Historically, that choice has come down to one question: does the patient look strong enough to handle FOLFIRINOX?

The tumor's biology has rarely entered that conversation. New data from Irving, Texas-based Caris Life Sciences suggests it should. According to the company's validation dataset, roughly 55% of patients with pancreatic ductal adenocarcinoma (PDAC) may not need the more intensive regimen, a figure Caris shared with AIM Media House ahead of publication.

The tool making that determination is already in wide use. Caris says it profiled approximately 8,500 PDAC samples through its MI Cancer Seek platform in 2025, ordered by more than 9,800 physicians across more than 3,900 sites. The validation data is arriving after broad deployment.

What the Tool Shows Physicians

The Caris signature, embedded inside MI Cancer Seek, reads each tumor using two sequencing methods. Whole Exome Sequencing maps the mutations in a tumor's DNA. Whole Transcriptome Sequencing reads which genes are actively switched on or off at the time of testing. That combined data feeds into CodeAI, Caris's proprietary AI platform, which the company says draws on molecular profiles from more than 550,000 patients to generate a treatment prediction.